AVTX vs RF
Avalo Therapeutics Inc (AVTX) versus RF (RF) — a side-by-side from cached financials, not a winner call.
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
RF (RF) common stock.
Latest reported AVTX revenue for 2024-12-31 was $441.0K. Net income was -$35.1M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
RF does not have a complete income-statement cache yet.
AVTX currently screens at market cap $51.5M and trailing P/E 0.0. RF currently screens at market cap $0.
Not investment advice. Open the AVTX and RF stock pages for the full models.
Not investment advice.